this study alone will take us to $100+
wow three incredible reports since Fri Close !!
Yahoo Finance 12/8/13
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
U.S. Food and Drug Administration Approves Gileadâ€™s Sovaldiâ„¢ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Do the DD.
Wall Street Journal
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application?
Acadia said the FDA agreed the company had enough compelling data for pimavanserin, its lead drug candidate proposed for treating for Parkinson’s disease psychosis.The FDA usually requires at least two successful late-stage trials, but will accept a single trial under certain circumstances, such as a drug that satisfies an unmet medical need
yes they do that's why there are SEC filing dummy